Stock Track | Intellia Therapeutics Plummets 5.01% Following Wolfe Research Downgrade on Nexig Safety Concerns

Stock Track11-13

Intellia Therapeutics (NTLA) saw its stock plummet 5.01% in intraday trading after Wolfe Research downgraded the company from Outperform to Peer Perform. The significant drop comes as investors react to concerns about the safety profile of one of Intellia's key products.

According to the downgrade report, Wolfe Research cited safety issues related to Intellia's product nexig as the primary reason for the rating change. The firm removed its price target for NTLA stock, indicating a cautious stance on the company's near-term prospects. This development has raised questions about the potential impact on Intellia's drug pipeline and future revenue streams.

The sharp decline in Intellia's stock price reflects the market's sensitivity to safety concerns in the biotechnology sector. As investors digest this news, it may also lead to increased scrutiny of other gene-editing companies and their respective product safety profiles. The movement underscores the volatile nature of biotech stocks, particularly when faced with regulatory or safety challenges.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172518764?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 00:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172518764","market":"sg","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Plummets 5.01% Following Wolfe Research Downgrade on Nexig Safety Concerns","media":"Stock Track","content":"<p>Intellia Therapeutics (NTLA) saw its stock plummet 5.01% in intraday trading after Wolfe Research downgraded the company from Outperform to Peer Perform. The significant drop comes as investors react to concerns about the safety profile of one of Intellia's key products.</p>\n\n<p>According to the downgrade report, Wolfe Research cited safety issues related to Intellia's product nexig as the primary reason for the rating change. The firm removed its price target for NTLA stock, indicating a cautious stance on the company's near-term prospects. This development has raised questions about the potential impact on Intellia's drug pipeline and future revenue streams.</p>\n\n<p>The sharp decline in Intellia's stock price reflects the market's sensitivity to safety concerns in the biotechnology sector. As investors digest this news, it may also lead to increased scrutiny of other gene-editing companies and their respective product safety profiles. The movement underscores the volatile nature of biotech stocks, particularly when faced with regulatory or safety challenges.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Plummets 5.01% Following Wolfe Research Downgrade on Nexig Safety Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Plummets 5.01% Following Wolfe Research Downgrade on Nexig Safety Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 00:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intellia Therapeutics (NTLA) saw its stock plummet 5.01% in intraday trading after Wolfe Research downgraded the company from Outperform to Peer Perform. The significant drop comes as investors react to concerns about the safety profile of one of Intellia's key products.</p>\n\n<p>According to the downgrade report, Wolfe Research cited safety issues related to Intellia's product nexig as the primary reason for the rating change. The firm removed its price target for NTLA stock, indicating a cautious stance on the company's near-term prospects. This development has raised questions about the potential impact on Intellia's drug pipeline and future revenue streams.</p>\n\n<p>The sharp decline in Intellia's stock price reflects the market's sensitivity to safety concerns in the biotechnology sector. As investors digest this news, it may also lead to increased scrutiny of other gene-editing companies and their respective product safety profiles. The movement underscores the volatile nature of biotech stocks, particularly when faced with regulatory or safety challenges.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1172518764","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172518764","pubTimestamp":1762966105,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics (NTLA) saw its stock plummet 5.01% in intraday trading after Wolfe Research downgraded the company from Outperform to Peer Perform. The significant drop comes as investors react...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"个股追踪|Wolfe Research因Nexig安全担忧下调评级后Intellia Therapeutics暴跌5.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics (NTLA) saw its stock plummet 5.01% in intraday trading after Wolfe Research downgraded the company from Outperform to Peer Perform. The significant drop comes as investors react to concerns about the safety profile of one of Intellia's key products.\nAccording to the downgrade report, Wolfe Research cited safety issues related to Intellia's product nexig as the primary reason for the rating change. The firm removed its price target for NTLA stock, indicating a cautious stance on the company's near-term prospects. This development has raised questions about the potential impact on Intellia's drug pipeline and future revenue streams.\nThe sharp decline in Intellia's stock price reflects the market's sensitivity to safety concerns in the biotechnology sector. As investors digest this news, it may also lead to increased scrutiny of other gene-editing companies and their respective product safety profiles. The movement underscores the volatile nature of biotech stocks, particularly when faced with regulatory or safety challenges.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172518764","isCrawlerRequest":true}